Neuraxpharm Acquires Leading Narcolepsy Treatments
Deal News | Jan 07, 2025 | PR Newswire Cision Neuraxpharm
Neuraxpharm Group, a prominent European pharmaceutical company specialized in therapies for central nervous system (CNS) disorders, has successfully acquired the narcolepsy treatments Provigil® (modafinil) and Nuvigil® (armodafinil) from international markets outside the U.S. This strategic acquisition supports Neuraxpharm's agenda to strengthen its CNS portfolio and expand into new markets like Australia and Mexico. Provigil® has seen significant sales in France, Spain, and Italy, while Nuvigil® is popular in markets such as Australia and Mexico. This move aligns with Neuraxpharm's strategy of growing solid CNS brands and enhancing their reach. The acquisition follows other strategic purchases, including portfolios from Sanofi and market-leading child epilepsy treatment Buccolam®, and thus underscores Neuraxpharm's focus on broadening their market presence worldwide. CEO Dr. Jörg-Thomas Dierks commented on the acquisition as an example of leveraging the company's neurology and international expertise to fulfill unmet patient needs. Financial details of the transaction were not disclosed.
Sectors
- Pharmaceuticals
- Healthcare
Geography
- Europe – Neuraxpharm is based in Europe with significant operations and sales in countries such as France, Spain, and Italy.
- Australia – Neuraxpharm plans to expand its presence with the introduction of Provigil and Nuvigil as well as other products like ublituximab in Australia.
- Mexico – Neuraxpharm has established an office in Mexico and includes the country as a significant sales market for Nuvigil.
Industry
- Pharmaceuticals – This industry is involved in the development, production, and commercialization of medications. Neuraxpharm operates within this industry, focusing on CNS disorders.
- Healthcare – This sector comprises companies providing medical services, manufacturing medical equipment or drugs, and facilitating the provision of healthcare to patients. Neuraxpharm's activities in CNS disorders align with this sector.
Financials
- Undisclosed – The financial details of the acquisition were not disclosed in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Neuraxpharm Group | Acquirer | Company | A European specialty pharmaceutical company focused on CNS disorders. |
| Provigil® (modafinil) | Acquired Product | Product | A trusted narcolepsy treatment acquired by Neuraxpharm. |
| Nuvigil® (armodafinil) | Acquired Product | Product | A narcolepsy treatment acquired by Neuraxpharm. |
| Sanofi | Vendor of Previous Portfolios | Company | A multinational pharmaceutical company from which Neuraxpharm previously acquired product portfolios. |
| Dr. Jörg-Thomas Dierks | CEO | Person | CEO of Neuraxpharm Group. |